220 related articles for article (PubMed ID: 31754034)
1. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Banerjee S; Wei T; Wang J; Lee JJ; Gutierrez HL; Chapman O; Wiley SE; Mayfield JE; Tandon V; Juarez EF; Chavez L; Liang R; Sah RL; Costello C; Mesirov JP; de la Vega L; Cooper KL; Dixon JE; Xiao J; Lei X
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24881-24891. PubMed ID: 31754034
[TBL] [Abstract][Full Text] [Related]
2. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Banerjee S; Ji C; Mayfield JE; Goel A; Xiao J; Dixon JE; Guo X
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8155-8160. PubMed ID: 29987021
[TBL] [Abstract][Full Text] [Related]
3. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Guo X; Wang X; Wang Z; Banerjee S; Yang J; Huang L; Dixon JE
Nat Cell Biol; 2016 Feb; 18(2):202-12. PubMed ID: 26655835
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles of DYRK2 in cancer.
Tandon V; de la Vega L; Banerjee S
J Biol Chem; 2021; 296():100233. PubMed ID: 33376136
[TBL] [Abstract][Full Text] [Related]
5. Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo.
Tandon V; Vala RM; Chen A; Sah RL; Patel HM; Pirrung MC; Banerjee S
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35088066
[TBL] [Abstract][Full Text] [Related]
6. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
Liu L; Fu Y; Zheng Y; Ma M; Wang C
Phytomedicine; 2020 Nov; 78():153312. PubMed ID: 32866906
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of HSF1 and DYRK2 impedes cancer progression.
Tandon V; Moreno R; Allmeroth K; Quinn J; Wiley SE; Nicely LG; Denzel MS; Edwards J; de la Vega L; Banerjee S
Biosci Rep; 2023 Jan; 43(1):. PubMed ID: 36622366
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Uddin MM; Zou Y; Sharma T; Gatla HR; Vancurova I
PLoS One; 2018; 13(8):e0201858. PubMed ID: 30089134
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Yerlikaya A; DoKudur H
Mol Biol (Mosk); 2010; 44(5):859-66. PubMed ID: 21090173
[TBL] [Abstract][Full Text] [Related]
10. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
11. The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Moreno R; Banerjee S; Jackson AW; Quinn J; Baillie G; Dixon JE; Dinkova-Kostova AT; Edwards J; de la Vega L
Cell Death Differ; 2021 May; 28(5):1563-1578. PubMed ID: 33268814
[TBL] [Abstract][Full Text] [Related]
12. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Deshmukh RR; Kim S; Elghoul Y; Dou QP
J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2.
Morrugares R; Correa-Sáez A; Moreno R; Garrido-Rodríguez M; Muñoz E; de la Vega L; Calzado MA
Cell Mol Life Sci; 2020 Jul; 77(13):2621-2639. PubMed ID: 31605148
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors induce AMPK activation via CaMKKβ in human breast cancer cells.
Deshmukh RR; Dou QP
Breast Cancer Res Treat; 2015 Aug; 153(1):79-88. PubMed ID: 26227473
[TBL] [Abstract][Full Text] [Related]
15. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
Raninga PV; Lee A; Sinha D; Dong LF; Datta KK; Lu X; Kalita-de Croft P; Dutt M; Hill M; Pouliot N; Gowda H; Kalimutho M; Neuzil J; Khanna KK
Theranostics; 2020; 10(12):5259-5275. PubMed ID: 32373211
[No Abstract] [Full Text] [Related]
16. Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer.
Adwal A; Kalita-de Croft P; Shakya R; Lim M; Kalaw E; Taege LD; McCart Reed AE; Lakhani SR; Callen DF; Saunus JM
Life Sci Alliance; 2020 Jul; 3(7):. PubMed ID: 32423906
[TBL] [Abstract][Full Text] [Related]
17. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
18. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Nek2 by small molecules affects proteasome activity.
Meng L; Carpenter K; Mollard A; Vankayalapati H; Warner SL; Sharma S; Tricot G; Zhan F; Bearss DJ
Biomed Res Int; 2014; 2014():273180. PubMed ID: 25313354
[TBL] [Abstract][Full Text] [Related]
20. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
